With 0.97 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.16 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.36 whereas the lowest price it dropped to was $1.26. The 52-week range on PLX shows that it touched its highest point at $1.90 and its lowest point at $0.82 during that stretch. It currently has a 1-year price target of $14.00. Beta for the stock currently stands at 0.61.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PLX was up-trending over the past week, with a rise of 13.27%, but this was up by 18.52% over a month. Three-month performance surged to 26.73% while six-month performance rose 15.32%. The stock lost -24.26% in the past year, while it has lost -28.09% so far this year. A look at the trailing 12-month EPS for PLX yields -0.22 with Next year EPS estimates of 0.62. For the next quarter, that number is 0.06. This implies an EPS growth rate of -33.33% for this year and 933.33% for next year.
Float and Shares Shorts:
At present, 72.95 million PLX shares are outstanding with a float of 62.88 million shares on hand for trading. On 2024-10-15, short shares totaled 3.1 million, which was 421.0 higher than short shares on 1726185600. In addition to Mr. Dror Bashan as the firm’s President, CEO & Director, Mr. Eyal Rubin M.B.A. serves as its Senior VP, CFO, Treasurer & Corporate Secretary.
Institutional Ownership:
Through their ownership of 0.07998 of PLX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, PLX reported revenue of $13474000.0 and operating income of -$2427000.0. The EBITDA in the recently reported quarter was -$1586000.0 and diluted EPS was -$0.03.
